Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etelcalcetide in hemodialysis patients with secondary hyperparathyroidism
NCT01254565Phase 2Completed
- Sponsor
- KAI Pharmaceuticals
- Start
- Feb 2011
- Primary completion
- Jul 2011
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of etelcalcetide in secondary hyperparathyroidism (SHPT), sponsored by KAI Pharmaceuticals. Started Feb 2011; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01254565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01254565.